Tandem Diabetes Care (TNDM)

• Market cap: $827M
• 1 day: 1.07%
• 5 days: 13.33%
• 1 month: -27.32%
• 3 months: -43.02%
• 6 months: -63.56%
• Year to date: -65.85%
• 1 year: -72.37%
• 5 years: -88.60%
• 10 years: -89.23%
• Sector: Healthcare
• Industry: Medical Devices

About: Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Employees: 2,650

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,145% more call options, than puts

Call options by funds: $53.9M | Put options by funds: $4.33M

69% more repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 68

11.3% more ownership

Funds ownership: 109.87% [Q1] → 121.17% (+11.3%) [Q2]

7% more capital invested

Capital invested by funds: $1.4B [Q1] → $1.5B (+$103M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

2% less first-time investments, than exits

New positions opened: 40 | Existing positions closed: 41

2% less funds holding

Funds holding: 272 [Q1] → 266 (-6) [Q2]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $11 10% downside
• Avg. target: $21 73% upside
• High target: $51 317% upside

9 analyst ratings

• positive: 3 33%
• neutral: 6 67%
• negative: 0 0%

Citigroup Joanne Wuensch	10% downside $11	Neutral Maintained	21 Aug 2025
Lake Street Brooks O'Neil	2% downside $12	Hold Downgraded	11 Aug 2025
Barclays Matt Miksic	317% upside $51	Overweight Maintained	8 Aug 2025
Canaccord Genuity William Plovanic	96% upside $24	Buy Maintained	7 Aug 2025
UBS Danielle Antalffy	39% upside $17	Neutral Maintained	7 Aug 2025